Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FHDA5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $99,505
Award facts
- Contract value 100% obligated
- $99,504.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $99,504.72 to DMS Pharmaceutical Group Inc. for the supply of STELARA 90 mg/ml syringes. This firm fixed-price delivery order, awarded on January 21, 2026, with an ultimate completion date of February 11, 2026, represents a procurement executed under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The product being delivered—STELARA, a biologic immunosuppressant—supports the Department of Defense's pharmaceutical supply needs for military healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award indefinite delivery contract with the Defense Logistics Agency (contract SPE2DR), which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036. The PPV-G GEN V represents a broader $30.3 billion acquisition strategy designed to provide regional prime vendor contractors to supply a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense global healthcare operations. DMS Pharmaceutical Group's established performance on numerous prior delivery orders demonstrates its capability to fulfill the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FHDA5?
SPE2DR26FHDA5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FHDA5 worth?
The government has obligated $99,505 on SPE2DR26FHDA5.
Is contract SPE2DR26FHDA5 an order under another contract?
Yes. SPE2DR26FHDA5 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHDA5 competed?
The extent of competition for SPE2DR26FHDA5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award